Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionAviva Plc
Latest Disclosed Ownership222,452 shares
Latest Disclosed Value $ 99,333,716
Aviva Plc reports 2.89% increase in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On May 14, 2026 - Aviva Plc filed a 13F-HR form disclosing ownership of 222,452 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $99,333,716 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 12, 2026 disclosing 216,211 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of 2.89% during the quarter. The current value of the position is $95,285,090 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 222,452 6,241 2.89 99,334 1.34 0.1666
2026-02-12 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 216,211 11,322 5.53 98,021 22.16 0.1653
2025-11-13 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 204,889 12,229 6.35 80,243 -6.45 0.1458
2025-08-07 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 192,660 11,970 6.62 85,772 -2.09 0.1771
2025-05-15 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 180,690 25,200 16.21 87,602 39.91 0.2114
2025-02-13 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 155,490 30,650 24.55 62,616 7.85 0.1626
2024-11-14 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 124,840 2,923 2.40 58,061 1.60 0.1504
2024-08-02 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 121,917 23,916 24.40 57,145 39.49 0.1584
2024-05-14 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 98,001 -28,982 -22.82 40,965 -20.71 0.1349
2024-02-09 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 126,983 17,357 15.83 51,668 35.54 0.1852
2023-11-13 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 109,626 8,816 8.75 38,121 7.46 0.1603
2023-08-10 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 100,810 -55,572 -35.54 35,476 -28.00 0.1445
2023-05-12 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 156,382 4,121 2.71 49,271 12.06 0.2231
2023-02-14 2022-12-31 13F/A-2 VERTEX PHARMACEUTICALS COM 92532F100 152,261 -18,744 -10.96 43,970 -11.20 0.2162
2023-02-10 2022-12-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 152,261 -18,744 4,744 0.0226
2023-02-09 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 152,261 -18,744 44 0.2113
2022-11-14 2022-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 171,005 -23,816 -12.22 49,513 -9.81 0.2854
2022-08-04 2022-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 194,821 47,073 31.86 54,899 42.38 0.2921
2022-05-13 2022-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 147,748 54,224 57.98 38,558 87.74 0.1928
2022-02-10 2021-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 93,524 -8,617 -8.44 20,538 10.85 0.0861
2021-11-12 2021-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 102,141 6,025 6.27 18,527 -4.40 0.0826
2021-08-10 2021-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 96,116 9,156 10.53 19,380 3.71 0.0850
2021-05-13 2021-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 86,960 -416 -0.48 18,687 -9.51 0.0913
2021-02-10 2020-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 87,376 3,535 4.22 20,650 -9.49 0.1074
2020-11-12 2020-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 83,841 -2,712 -3.13 22,815 -9.20 0.1346
2020-08-13 2020-06-30 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 86,553 -4,520 -4.96 25,127 15.95 0.1566
2020-08-13 2020-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 86,553 -4,520 25,127 76,070.2060
2020-05-14 2020-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 91,073 984 1.09 21,671 9.87 0.1588
2020-02-10 2019-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 90,089 -504 -0.56 19,725 28.52 0.1195
2019-11-12 2019-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 90,593 -3,548 -3.77 15,348 -11.10 0.1040
2019-07-30 2019-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 94,141 -2,340 -2.43 17,264 -2.73 0.1186
2019-05-14 2019-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 96,481 175 0.18 17,748 11.21 0.1191
2019-02-12 2018-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 96,306 -26,489 -21.57 15,959 -32.57 0.1190
2018-11-13 2018-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 122,795 -4,353 -3.42 23,668 9.52 0.1298
2018-08-01 2018-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 127,148 -835 -0.65 21,610 3.60 0.1275
2018-05-14 2018-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 127,983 -12,550 -8.93 20,859 -0.95 0.1275
2018-02-13 2017-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 140,533 -17,545 -11.10 21,060 -12.37 0.1192
2017-11-13 2017-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 158,078 3,420 2.21 24,034 20.58 0.1293
2017-08-07 2017-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 154,658 1,980 1.30 19,932 19.39 0.1114
2017-05-15 2017-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 152,678 -8,487 -5.27 16,695 40.48 0.0956
2017-02-13 2016-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 161,165 10,610 7.05 11,884 -9.51 0.0710
2016-11-14 2016-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 150,555 3,286 2.23 13,133 3.70 0.0819
2016-08-05 2016-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 147,269 11,649 8.59 12,665 17.49 0.0868
2016-05-12 2016-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 135,620 1,456 1.09 10,780 -36.15 0.0801
2016-02-11 2015-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 134,164 -797 -0.59 16,882 20.12 0.1280
2015-11-12 2015-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 134,961 -1,808 -1.32 14,054 -16.79 0.1164
2015-08-06 2015-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 136,769 8,100 6.30 16,889 11.27 0.1195
2015-05-14 2015-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 128,669 128,669 0.00 15,179 0.1040
2015-02-05 2014-12-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 0 -96,878 -100.00 0 -100.00
2014-11-13 2014-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 96,878 -80 -0.08 10,880 18.52 0.0861
2014-08-13 2014-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 96,958 200 0.21 9,180 34.15 0.0702
2014-05-14 2014-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 96,758 4,810 5.23 6,843 0.16 0.0555
2014-02-13 2013-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 91,948 8,344 9.98 6,832 7.78 0.0571
2013-11-13 2013-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 83,604 -254,788 -75.29 6,339 -76.55 0.0556
2013-08-01 2013-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 338,392 338,392 27,028 0.2732
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.